Further, Eμ-myc/apaf1−/− lymphomas displayed loss of LCB-I with concurrent gain of LCB-II, a biochemical feature of autophagy.19 This intriguing result is similar to previous data showing the ability of HDAC inhibitors to induce autophagy in the same Eμ-myc/apaf1−/− lymphoma model.18 This work also demonstrated that HDAC inhibitor induced autophagy mediated significant in vivo therapeutic efficacy in mice bearing Eμ-myc/apaf1−/− lymphomas. Here, HDAC9 is linked to lymphoma.